CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 139 enrolled
Drug / intervention
Rituximab +5 moredrug
Likely dose
Rituximab 1400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02406092
NCT02406092Phase 3Completed

An Open-Label, Multinational, Multicenter, Phase IIIB Study to Assess Safety of Rituximab Following Subcutaneous Administration in Patients With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3A

Hoffmann-La Roche·interventional·Posted Apr 2, 2015·Updated Nov 21, 2024

In Brief

A Phase 3 clinical trial evaluating Rituximab, Cyclophosphamide, and 4 other interventions for Non-Hodgkin Lymphoma. Completed, enrolled 139 participants across 13 sites in 3 countries.

Detailed Summary

This open-label, single-arm study will evaluate the safety of rituximab subcutaneously (SC) administered during first line treatment for follicular non-Hodgkin's lymphoma (NHL) (Induction and/or Maintenance treatment plus 24 months of follow up), or diffuse large B-cell lymphoma (DLBCL) (treatment plus 24 months of follow-up).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAlgeria, Morocco, Tunisia
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedApr 2, 2015
Enrollment StartOct 13, 2015
Primary CompletionJun 30, 2021
TodayJul 2, 2026
Enrollment to primary: 5.7 yearsPosted 11.3 years ago

Interventions

Rituximabdrug

Rituximab SC 1400 mg

Cyclophosphamidedrug

Cyclophosphamide will be administered as per standard local practice.

Doxorubicindrug

Doxorubicin will be administered as per standard local practice.

Vincristinedrug

Vincristine will be administered as per standard local practice.

Prednisonedrug

Prednisone will be administered as per standard local practice.

Fludarabinedrug

Fludarabine will be administered as per standard local practice.